Allergan Submits New Drug Application for Investigational AGN-190584 for the Treatment of Presbyopia

Allergan, an AbbVie company, announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.

Approximately 128 million adults in the U.S. experience presbyopia. Yet, compared to other eye-related conditions, there is a much lower awareness of presbyopia by name.

“Presbyopia is a significant source of frustration for most adults over age 40 who find current treatments inconvenient or invasive,” said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. “If approved, AGN-190584 is expected to be the first eye drop to treat presbyopia, providing a novel option to those affected in the U.S.”

The NDA is based primarily on data from two Phase 3 GEMINI 1 and GEMINI 2 clinical studies, which evaluated the efficacy, safety and tolerability of AGN-190584 (pilocarpine 1.25%). A total of 750 patients were randomized in a one-to-one ratio of vehicle (placebo) to AGN-190584. In both studies, AGN-190584 met the primary endpoint reaching statistical significance in improvement in near vision in mesopic (in low light) conditions without a loss of distance vision vs. the vehicle. There were no treatment emergent serious adverse events observed in any AGN-190584 treated participants. The most common treatment emergent non-serious adverse events occurring at a frequency of ≥5% in AGN-190584 treated participants were headache and conjunctival hyperemia.

Click HERE for the full press release.

Featured Posts

Transitions®: the clear lens that adapts to light for the perfect protection!

Did you know Transitions® has a lens for all your patients experiencing any level of light sensitivity?

Learn More

In Perfect Harmony

Dress your eyes in a showstopping synchronous design from VANNI's Tandem collection.

Learn More

Transitions®: the clear lens that adapts to light for the perfect protection!

Did you know Transitions® has a lens for all your patients experiencing any level of light sensitivity?

Read more

SightGlass Vision Releases First White Paper on Diffusion Optics Technology™

SightGlass Vision announced the release of its first white paper regarding the company’s Diffusion Optics Technology™ (DOT 0.2) spectacle lenses.

Read more

Companies Nominated at the 30th SILMO d’Or

The 2023 SILMO d'Or nominees are...

Read more

Nicolas Fafiotte Appointed President of the 2023 SILMO D’OR Awards

A graduate of the ESMOD School of Fashion Design, Nicolas Fafiotte trained in Paris before moving to Lyon in the early 2000s.

Read more

Transitions®: the clear lens that adapts to light for the perfect protection!

Did you know Transitions® has a lens for all your patients experiencing any level of light sensitivity?

Learn More

In Perfect Harmony

Dress your eyes in a showstopping synchronous design from VANNI's Tandem collection.

Learn More

Transitions®: the clear lens that adapts to light for the perfect protection!

Did you know Transitions® has a lens for all your patients experiencing any level of light sensitivity?

Read More

SightGlass Vision Releases First White Paper on Diffusion Optics Technology™

SightGlass Vision announced the release of its first white paper regarding the company’s Diffusion Optics Technology™ (DOT 0.2) spectacle lenses.

Read More

Companies Nominated at the 30th SILMO d’Or

The 2023 SILMO d'Or nominees are...

Read More

Nicolas Fafiotte Appointed President of the 2023 SILMO D’OR Awards

A graduate of the ESMOD School of Fashion Design, Nicolas Fafiotte trained in Paris before moving to Lyon in the early 2000s.

Read More

Transitions®: the clear lens that adapts to light for the perfect protection!

Did you know Transitions® has a lens for all your patients experiencing any level of light sensitivity?

Learn More

In Perfect Harmony

Dress your eyes in a showstopping synchronous design from VANNI's Tandem collection.

Learn More

Transitions®: the clear lens that adapts to light for the perfect protection!

Did you know Transitions® has a lens for all your patients experiencing any level of light sensitivity?

Read more

SightGlass Vision Releases First White Paper on Diffusion Optics Technology™

SightGlass Vision announced the release of its first white paper regarding the company’s Diffusion Optics Technology™ (DOT 0.2) spectacle lenses.

Read more

Companies Nominated at the 30th SILMO d’Or

The 2023 SILMO d'Or nominees are...

Read more

Nicolas Fafiotte Appointed President of the 2023 SILMO D’OR Awards

A graduate of the ESMOD School of Fashion Design, Nicolas Fafiotte trained in Paris before moving to Lyon in the early 2000s.

Read more

Transitions®: the clear lens that adapts to light for the perfect protection!

Did you know Transitions® has a lens for all your patients experiencing any level of light sensitivity?

Learn More

In Perfect Harmony

Dress your eyes in a showstopping synchronous design from VANNI's Tandem collection.

Learn More

Transitions®: the clear lens that adapts to light for the perfect protection!

Did you know Transitions® has a lens for all your patients experiencing any level of light sensitivity?

Read more

SightGlass Vision Releases First White Paper on Diffusion Optics Technology™

SightGlass Vision announced the release of its first white paper regarding the company’s Diffusion Optics Technology™ (DOT 0.2) spectacle lenses.

Read more

Companies Nominated at the 30th SILMO d’Or

The 2023 SILMO d'Or nominees are...

Read more

Nicolas Fafiotte Appointed President of the 2023 SILMO D’OR Awards

A graduate of the ESMOD School of Fashion Design, Nicolas Fafiotte trained in Paris before moving to Lyon in the early 2000s.

Read more